GlaxoSmithKline Pharmaceuticals Limited has recorded Q1 FY22 revenue at Rs 773 crores recording a growth of 19%.

Profit Before Tax for the quarter at Rs.164 crores recorded a growth of 10%. The company also announced its decision to transfer its rights in relation to the /odex and Ostoca/cium brands to GlaxoSmithKline Asia Private Limited, subject to shareholder approval, for an aggregate consideration of Rs 1,649 crore.

Commenting on the results, Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited said, "We continue to show remarkable resilience and deliver growth despite the headwinds caused by the COVID-19 pandemic. Our pharmaceutical manufacturing team worked round the clock to fulfill significantly increased demand for our key brands, especially for Ca/pol (paracetamol). This effort ensured that patients continued to have access to this important medication during the pandemic. While our vaccines business was impacted due to low vaccination rates, many of our key brands witnessed strong growth fuelled by disciplined execution, enhanced digital capabilities and agility in the market resulting in market share gains."

Commenting on the transfer of brand rights, Venkatesh commented, "As part of our parent GSK pie's new ambition to create two world class companies in Pharmaceuticals and Consumer Healthcare, we have decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited. The transaction is expected to be completed before the end of the year, subject to shareholder approval and the customary closing conditions, including relevant regulatory approvals."